bims-engexo Biomed News
on Engineered exosomes
Issue of 2026–11–08
fifteen papers selected by
Ravindran Jaganathan, Universiti Kuala Lumpur



  1. Med Sci Monit. 2026 Nov 02. 32 e953961
      Exosomes, as critical mediators of intercellular communication, transport nucleic acids, proteins, and lipids that drive osteosarcoma (OS) progression and dynamically remodel the tumor microenvironment. Their distinctive biological properties-including low immunogenicity, high stability, and inherent targeting capability-position them as versatile tools across the entire OS management continuum, from early non-invasive diagnosis via liquid biopsy to targeted biotherapy and postoperative bone regeneration through coordinated osteogenesis-angiogenesis coupling. This review first outlines the epidemiological features and principal clinical bottlenecks of OS, then systematically summarizes exosome biogenesis, cellular uptake mechanisms, and the key molecular pathways through which exosomal cargoes regulate OS malignancy. We highlight emerging evidence that exosomal biomarkers enable real-time disease monitoring and that engineered exosomes serve as precision nanocarriers for therapeutic delivery. Notably, we emphasize recent insights into exosome-mediated crosstalk with immune cells within the osteoimmune microenvironment, their role in orchestrating vascularized bone formation, and advances in exosome-functionalized biomaterial scaffolds that effectively bridge tissue engineering with oncology. The clinical relevance of these findings lies in their potential integration into a unified diagnostic-therapeutic-regenerative paradigm, which may help overcome current limitations in surgical outcomes and chemoresistance. Nevertheless, clinical translation remains hindered by persistent challenges, including the lack of standardized isolation and characterization protocols, suboptimal in vivo delivery efficiency, batch-to-batch variability, and insufficient long-term safety data. Addressing these obstacles will require further mechanistic studies and multicenter clinical trials to establish robust regulatory frameworks. This article aims to review the roles of osteosarcoma-derived exosomes in tumor progression, chemoresistance, and bone regeneration, as well as their potential for drug delivery.
    DOI:  https://doi.org/10.12659/MSM.953961
  2. Discov Nano. 2026 Nov 03. pii: 596. [Epub ahead of print]21(1):
      Exosomes have emerged as a promising class of next-generation nanocarriers at the intersection of regenerative medicine and drug delivery. Compared with conventional synthetic nanocarriers and stem cell-based therapies, exosomes offer unique advantages, including intrinsic biocompatibility, low immunogenicity, blood-barrier penetration, and natural intercellular cargo transfer. This review critically examines exosome biology, beginning with their biogenesis, structural composition, and roles in cellular homeostasis, immune regulation, autophagy, and tissue repair. Particular emphasis is placed on their therapeutic relevance in wound healing, neuroregeneration, cardiovascular repair, musculoskeletal regeneration, and cancer. The review further discusses major strategies for exosomal cargo engineering, including passive loading, electroporation, sonication, transfection-based approaches, extrusion, freeze-thaw treatment, and chemical functionalization. In addition, scaffold-assisted delivery systems and hybrid exosome-synthetic nanocarrier platforms are highlighted as important advances for improving local retention, targeting precision, and controlled release. Despite strong preclinical promise, translation remains limited by challenges in scalable manufacturing, purification, batch consistency, loading efficiency, potency assessment, and regulatory standardization. Future progress in this field will depend on the development of scalable and GMP-compatible exosome manufacturing, standardized purification and characterization methods, validated potency assays, regulatory-aligned quality control, and artificial intelligence (AI) engineering strategies to translate exosome-based platforms into safe, reproducible, and clinically effective regenerative therapeutics.
    Keywords:  Artificial Intelligence; Exosomes; Immunomodulation; Nanocarrier; Regenerative medicine
    DOI:  https://doi.org/10.1186/s11671-026-05089-1
  3. Eur J Pharmacol. 2026 Nov 04. pii: S0014-2999(26)00971-4. [Epub ahead of print] 179489
      Dendritic cells (DCs) are the most well-known immune cells for cancer immunotherapy progress. The engineered extracellular vesicles (EVs) from DCs (DCs-EVs) for immunotherapy have emerged as a novel and effective therapeutic approach because they naturally contribute to regulating immune responses by transporting therapeutic agents to target cells with minimal toxicity and high specificity. DCs-EVs, are heterogeneous extracellular particles, generally contribute to intracellular communication and immune regulation due to the presence of immune-regulatory molecules, antigens, major histocompatibility complexes, and co-stimulatory molecules. As a result, engineered DCs-EVs are defined as lipid bilayer delimited EVs released by DCs that have been intentionally pre- or post-isolated to change their surface composition, cargo, targeting properties, biodistribution, or immunomodulatory function. DCs-EVs have been examined for breast cancer, colorectal cancer, melanoma, and glioblastoma. Although engineered DCs-EVs have demonstrated hopeful results in preclinical experiments, for clinical translation, some limitations remain to be addressed in further studies. In addition, for clinical trials, these EVs must comply with good manufacturing practice (GMP). This narrative review was informed by a structured literature search about the application of engineered DCs-EVs in cancer immunotherapy utilizing sources like Google Scholar, Scopus, ScienceDirect, PubMed, and WOS. Furthermore, it discussed EVs biology, engineering methods, and clinical trials, as well as outlined challenges and perspectives in this field.
    Keywords:  Cancer immunotherapies; Dendritic cells; Engineering methods; Exosomes; Extracellular vesicles
    DOI:  https://doi.org/10.1016/j.ejphar.2026.179489
  4. Biomed Pharmacother. 2026 Nov;pii: S0753-3322(26)01058-9. [Epub ahead of print]204 120022
      Curcumin has diverse pharmacological activities but poor water solubility, rapid degradation, extensive metabolism, and very low oral bioavailability limit its therapeutic use. This review evaluates mesenchymal stem cell-derived exosomes (MSC-Exo; MSC-derived small extracellular vesicles per MISEV2023) as natural nanocarriers for curcumin delivery and the barriers to clinical translation. Curcumin-loaded MSC-Exo (Cur@Exos) can improve curcumin stability, sustain release, enhance target-tissue accumulation, and cross biological barriers such as the blood-brain barrier. Compared with synthetic nanocarriers, MSC-Exo may offer better biocompatibility, immune evasion, and tissue tropism, but these properties depend on source and preparation; proteomes, miRNA cargoes, and functions differ among bone marrow-, umbilical cord-, and adipose-derived MSCs. Encapsulation efficiency, batch consistency, scalability, and storage stability also remain suboptimal. Preclinical studies show Cur@Exos benefits in neurodegenerative diseases, rheumatoid arthritis, liver disease, wound healing, bone defects, and sepsis-associated kidney injury. However, findings are limited by heterogeneity in exosome sources, preparation, loading methods, and animal models; small samples and short follow-up; inconsistent dose metrics (particle number vs. protein content); and lack of standardized process and outcome criteria, reference materials, and potency assays. Long-term safety remains inadequately established: current evidence covers only short-term single or repeated dosing; ≥ 6-month repeat-dose toxicology with anti-drug antibody and complement monitoring, predictive immunogenicity screening, tumorigenicity assessment, potency-based batch release testing, and clinical efficacy data are lacking. MSC-Exo is a promising curcumin-delivery platform, but translation requires standardized manufacturing, globally harmonized quality control, improved scalability, systematic safety evaluation, well-designed multicenter trials, and a clarified international regulatory pathway.
    Keywords:  Clinical translation; Curcumin; Extracellular vesicles; GMP manufacturing; Mesenchymal stem cell-derived exosomes; Natural nanocarriers
    DOI:  https://doi.org/10.1016/j.biopha.2026.120022
  5. PLoS Pathog. 2026 Nov 04. 22(11): e1014781
      Bacterial diseases are primarily managed with antibiotics, but vaccination is widely acknowledged as the most efficacious strategy for their prevention. Bacterial polysaccharides serve as key protective antigens in hosts and are therefore consistently prioritized as targets for bacterial vaccine development. Polysaccharide-conjugated vaccines have emerged as a promising and effective approach to combat multidrug-resistant bacteria. In order to construct a vaccine carrier capable of delivering bacterial polysaccharides while inducing robust immune response, this study utilized outer membrane vesicles (OMVs) derived from Salmonella Typhimurium as the vaccine carrier instead of the traditional adjuvant components to enhance the immunogenicity of polysaccharide vaccine. S. Typhimurium was genetically engineered to enable the controlled synthesis of LPS and glycoprotein, which were encapsulated within OMVs as two distinct polysaccharide vaccine formulations. This engineered delivery system was used to deliver the O-antigen polysaccharide of Shigella flexneri 3a, and subsequent validation in a murine model further confirmed that its ability to elicit an effective in vivo immune response. The polysaccharide delivery carrier platform established in this study provides a foundation for the subsequent multi-form delivery of bacterial polysaccharides in next-generation biological vaccines.
    DOI:  https://doi.org/10.1371/journal.ppat.1014781
  6. Adv Healthc Mater. 2026 Nov 02. pii: e71891. [Epub ahead of print]
      This study examined anti-transferrin receptor (TfR) nanobody-functionalized bacterial outer membrane vesicles (OMVs) as an engineered platform for improving Alzheimer's disease (AD)-like neuronal injury. Escherichia coli-derived OMVs were characterized for morphology, size distribution, surface charge, protein features, nanobody loading, residual endotoxin levels, endotoxin-associated inflammatory responses, and repeated-exposure immune-safety readouts, and were evaluated in neuronal-related cells and APP/PS1 mice. Engineered OMVs showed receptor-associated uptake and preferential brain-delivery signals, increased HT-22 cell viability, reduced apoptosis, and elevated mitophagy-associated markers including LC3-II, PINK1, and Parkin. OMV treatment also reduced cytosolic mtDNA abundance, DNA/cGAS colocalization, phosphorylation of STING/TBK1/IRF3, and inflammatory-marker expression. PINK1 or Parkin knockdown partially weakened OMV-associated mitochondrial and inflammatory readouts, whereas pharmacological autophagy modulation supported a contribution of autophagy-related processes without establishing selective PINK1/Parkin-dependent mitophagy in vivo. In APP/PS1 mice, OMV administration improved Morris water maze and rotarod performance and alleviated neuroinflammatory and histological injury-related changes. Overall, anti-TfR nanobody-modified OMVs were associated with enhanced receptor-related delivery, mitophagy-linked phenotypes, reduced cytosolic mtDNA/cGAS-STING-related inflammatory signaling, and improved AD-like outcomes, supporting further delivery-system optimization and mechanistic validation.
    Keywords:  Alzheimer's disease; cGAS‐STING signaling; mitophagy; nanobody; neuroinflammation; outer membrane vesicles
    DOI:  https://doi.org/10.1002/adhm.71891
  7. Nano Lett. 2026 Nov 04. 26(43): 14968-14978
      Engineered extracellular vesicles (EVs) are promising therapeutic carriers for cancer treatment, but preserving intrinsic therapeutic activity while incorporating multiple immunomodulatory functions remains a challenge. Here, we developed a modular engineering strategy that combines the genetic engineering of EV-producing cells with bioorthogonal click chemistry to construct multifunctional oncolytic extracellular vesicles (OEVs). Azide-functionalized OEVs were generated from CD40L-expressing cells infected with a capsid-engineered oncolytic adenovirus. A toll-like receptor 9 (TLR9) agonist was subsequently conjugated to the OEV surface through click chemistry, integrating immune stimulation while retaining the oncolytic activity. The engineered OEVs efficiently infected tumor cells, induced antigen-presenting cell activation, enhanced intratumoral CD8+ T-cell responses, promoted B-cell activation and tumor-specific antibody production, and improved the therapeutic efficacy of the immune checkpoint blockade. These findings demonstrated that combining genetic engineering with bioorthogonal chemistry provided a strategy for constructing multifunctional oncolytic EVs with coordinated cytotoxic and immunomodulatory activities, offering an approach to next-generation cancer immunotherapies.
    Keywords:  B-cell activation; click chemistry; extracellular vesicles; oncolytic virus; tumor immunotherapy
    DOI:  https://doi.org/10.1021/acs.nanolett.6c03597
  8. Biol Reprod. 2026 Nov 05. pii: ioag249. [Epub ahead of print]
      In vitro maturation (IVM) of oocytes plays a crucial role in assisted reproductive technologies in livestock production, enabling efficient large-scale embryos production and supporting genetics improvement programs. However, the efficiency of this technology remains limited as only a small proportion of cumulus-oocytes complexes (COCs) matured in vitro reach the blastocyst stage, which exhibit lower quality than those produced in vivo. Recent efforts have focused on delivering biological materials to cumulus cells during IVM to improve oocyte quality. Herein, we hypothesized that extracellular vesicles (EVs) isolated from ovarian follicular fluid (FF) can be engineered to deliver synthetic microRNAs (miRNAs) to cumulus cells during IVM. Here, we demonstrate for the first time that follicular fluid-derived EVs are enriched with synthetic miRNAs and successfully delivered to COCs, resulting in altered gene expression in cumulus cells, and transfer of miRNAs to the oocyte cytoplasm. Specifically, EVs loaded with bta-miR-20a-5p were effectively taken up by cumulus cells during IVM, enhanced PI3K/AKT signaling with significant increase in downstream genes, such EIF4b and GSK3, which are involved in cell cycle progression, DNA repair and protein synthesis. Additionally, bta-miR-20a-5p-loaded-EVs supplementation to COCs, during IVM, appeared to reduce cleavage and blastocyst development rates. Collectively, our findings demonstrated that engineered EVs can deliver a synthetic miRNA to COCs during IVM, representing highlighting their potential to modulate oocyte cytoplasm content and embryo development.
    Keywords:  early embryo development; exogenous miRNAs; extracellular vesicles; oocyte cytoplasm
    DOI:  https://doi.org/10.1093/biolre/ioag249
  9. Discov Nano. 2026 Nov 03. pii: 594. [Epub ahead of print]21(1):
      Exosome-mediated drug delivery recently emerged as a viable approach for enhancing the therapeutic effectiveness of antimicrobial medicines in combating multidrug-resistant (MDR) pathogenic bacteria. Due to their inherent biocompatibility, biomimetic membrane structure, and effective cargo transport abilities, exosomes confront numerous drawbacks linked to traditional antimicrobial delivery systems, such as suboptimal drug stability, restricted biofilm infiltration, insufficient intracellular delivery, and unintended toxicity. This analysis offers an extensive summary of the latest developments in exosome-facilitated antimicrobial delivery, emphasising the conveyance of antibiotics, antimicrobial peptides, nucleic acids, and hybrid nanotherapeutics. Processes through which exosomes increase antimicrobial effectiveness, such as improved biofilm infiltration, intracellular localisation, immune system modulation, and precise cargo delivery, are comprehensively discussed. Recent advancements in exosome manipulation, cargo-loading methodologies, hybrid exosome-centric systems, and pathogen-specific delivery techniques are critically reviewed. Furthermore, this review discusses critical translational obstacles including scalable production, cargo-loading efficacy, quality assurance, storage durability, regulatory harmonisation, and clinical application. The evidence gathered highlights the potential of exosome-based delivery systems as novel biomimetic nanocarriers in the battle against antimicrobial resistance. It also highlights the technological and regulatory developments required for their successful clinical application.
    Keywords:  Antimicrobial drug delivery; Antimicrobial resistance; Exosome; Extracellular vesicles; Hybrid nanocarrier system
    DOI:  https://doi.org/10.1186/s11671-026-05011-9
  10. Hum Cell. 2026 Nov 03. pii: 152. [Epub ahead of print]39(11):
      Extensive desmoplastic remodeling in pancreatic ductal adenocarcinoma (PDAC) limits the intratumoral access of therapeutic agents and contributes to treatment resistance. Here, we investigated the stromal uptake preference, fibrosis-modulating activity, and siRNA-loading capacity of human pancreatic stellate cell-derived exosomes (HPSC-Exos). HPSC-Exos were recovered through sequential centrifugation steps ending with ultracentrifugation. Nanoparticle tracking analysis (NTA) placed most detected particles within the 100-150 nm range, whereas immunoblotting identified CD9, CD81, and TSG101, but not Calnexin. Flow cytometry and confocal microscopy showed greater HPSC-Exo-associated fluorescence in cancer-associated fibroblasts (CAFs) than in PANC-1 and HEK-293T cells. Integrin αv and integrin β1 were detected in HPSC-Exo preparations, and RGD peptide competition reduced CAF uptake, supporting RGD-sensitive, integrin-associated interactions. Unloaded HPSC-Exos reduced fibrosis-associated protein expression and produced concentration-associated decreases in FAP, α-SMA, fibronectin, COL1A1, and COL3A1 mRNA levels by approximately 30-51% at 40 μg/mL. CAF wound closure at 24 h was reduced by approximately 68.6% and 81.7% following treatment with 20 and 40 μg/mL HPSC-Exos, respectively, relative to untreated controls. No significant reduction in the metabolic viability of HPSCs, HEK-293 T cells, or CAFs was observed at concentrations up to 80 μg/mL. Additionally, chemically modified siRNA directed against GLI2 (siGLI2) was incorporated into HPSC-Exos by electroporation, and the loaded preparations retained a predominantly nanoscale size distribution and CAF uptake comparable to unloaded HPSC-Exos. Collectively, HPSC-Exos exhibit preferential CAF-associated uptake and intrinsic modulation of fibrosis-associated phenotypes in vitro, while also supporting siRNA loading, providing a biological platform for further investigation in the PDAC stromal microenvironment.
    Keywords:  Biocompatibility; Exosomes; Fibrosis; Pancreatic cancer; Tumor microenvironment
    DOI:  https://doi.org/10.1007/s13577-026-01466-1
  11. Int J Nanomedicine. 2026 ;21 627425
      Extracellular vesicles (EVs) are nanoscale membrane-bound vesicles that mediate intercellular communication by transporting bioactive molecules, playing crucial roles in physiology and pathology. Recently, EVs have attracted considerable interest as drug delivery carriers for cancer therapy due to their biocompatibility, low immunogenicity, and intrinsic targeting capabilities. This review systematically summarizes EV biogenesis, classification, and characteristics, and thoroughly explores their applications in delivering chemotherapeutics, nucleic acids, and immunomodulators for cancer treatment. We emphasize engineering strategies to enhance EV targeting and therapeutic efficacy, including surface modification, cell source selection, and drug loading techniques. Additionally, we evaluate recent advances in overcoming tumor drug resistance and achieving combinational therapies, such as chemo-photothermal-immunotherapy, using EV platforms. Finally, we examine critical challenges hindering clinical translation, including standardized production, quality control, and scalable manufacturing. This comprehensive analysis aims to provide theoretical insights and practical guidance for developing EVs as next-generation drug delivery systems in cancer therapy.
    Keywords:  cancer therapy; clinical translation; drug delivery; engineering modification; extracellular vesicles; targeted therapy
    DOI:  https://doi.org/10.2147/IJN.S627425
  12. Mater Today Bio. 2026 Dec;41 103760
      Relative tight endothelium in the heart may be a barrier for drugs in the large molecule and nanoparticle formats to act on cardiomyocytes. We hypothesize that enhanced binding of large molecules or nanoparticles to the cardiac capillary endothelial cells can increase the transendothelial transport of these drugs to exert their effects on the cardiomyocytes beneath the endothelium. CD36 is densely localized on the membrane of myocardial endothelial cells and thus we engineered small extracellular vesicles (sEVs) to be coated with an analog of CD36 ligand fatty acids, KOdiA-PC. Further to trap more therapeutic sEVs in the myocardium, we conjugated the sEVs with ischemic myocardium- targeting peptide (IMT). These dual-modifications of sEVs resulted in markedly enhanced fluorescent retention in the MIRI heart, indicating the potential of this system as a promising drug delivery platform for ischemic myocardium. Thus we loaded the dually-modified sEVs with edaravone (EDV) and siPKA RNA to dampen the ROS and inhibit overactivated PKA in myocardium subjected to ischemia/reperfusion injury, making a multistage-targeting and multifunctional sEVs delivery system (KI-sEVs/siPKA/EDV). The results showed that KOdiA-PC modification significantly enhanced sEVs transendothelial transport efficiency, and dual-targeting modification dramatically increased the accumulation of sEVs in the heart. Intravenous injection of KI-sEVs/siPKA/EDV significantly decreased myocardial infarction size, improved cardiac function and reduced cardiac fibrosis in animals subjected to MIRI or MI. KI-sEVs/siPKA/EDV also showed good biocompatibility and low toxicity. Our study provides an innovative cardiac-targeting delivery strategy and offers a promising method for MIRI and Persistent coronary occlusion MI treatment.
    Keywords:  Cardiac-specific transendothelial transport; Edaravone; Multistage-targeting drug delivery system; Myocardial ischemia-reperfusion injury; PKA siRNA; Permanent MI
    DOI:  https://doi.org/10.1016/j.mtbio.2026.103760
  13. J Nanobiotechnology. 2026 Aug 07. pii: 1035. [Epub ahead of print]24(1):
      Senile osteoporosis (SOP) is an age-related skeletal disease characterized by progressive bone loss and the deterioration of bone microarchitecture. Promoting the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is a potential strategy for SOP intervention; however, achieving targeted regulation of BMSCs with translational feasibility remains challenging. Given the modifiability, biocompatibility, and production potential of bacterial extracellular vesicles (BEVs), this study constructed dual-targeted bioengineered BEVs (BT-BEVs-CS) via synthetic biology. These BT-BEVs-CS display the bone-targeting peptide Ser-Asp-Ser-Ser-Asp (SDSSD, BT), the chemokine receptor CXCR4, and SUMOylation activating enzyme subunit 1 (SAE1) to promote the osteogenic differentiation of BMSCs. In vitro and in vivo experiments showed that, via the synergistic action of CXCR4 and BT, BT-BEVs-CS targeted the bone microenvironment and were internalized by BMSCs. Mechanistic studies suggested that targeted delivery of SAE1 promoted the SUMOylation of N-acetyltransferase 10 (NAT10), thereby attenuating its ubiquitin-mediated degradation. Stabilized NAT10 subsequently supported the N4-acetylcytidine (ac4C) modification of the mRNA encoding phosphoglucose isomerase (PGI), enhancing PGI mRNA stability. This modification contributed to increased PGI expression, enhanced glycolytic activity, and improved energy support for the osteogenic differentiation of BMSCs. In vivo studies further showed that BT-BEVs-CS facilitated the osteogenic differentiation of BMSCs and ameliorated pathological bone loss in SOP mouse models. In summary, this study constructed bioengineered BT-BEVs-CS with bone-targeting and osteoinductive properties. This work provides insights into the mechanisms of the SAE1-NAT10/ac4C-PGI regulatory axis in post-translational modifications (PTMs), RNA epigenetic regulation, and glycolysis, offering a preclinical proof-of-concept for targeted nano-intervention strategies for SOP.
    Keywords:  BMSC; N4-acetylcytidine modification; NAT10; SAE1; SOP; SUMOylation
    DOI:  https://doi.org/10.1186/s12951-026-04820-5
  14. Curr Opin Chem Biol. 2026 Nov 04. pii: S1367-5931(26)00164-X. [Epub ahead of print]95 102815
      Genome editing technologies hold significant promise for the treatment of genetic disorders, but safe and efficient delivery remains a major barrier to their clinical translation. Cell-derived particles, including extracellular vesicles (EVs) and virus-like particles (VLPs), have emerged as promising non-viral delivery platforms, offering biological compatibility and the capacity to package and deliver genome editors as ribonucleoprotein (RNP) complexes in a transient manner that reduces the risk of off-target editing. The surface composition of these vehicles is shaped by their biogenesis pathway and their cell of origin, which in turn govern their cellular tropism. Through various engineering strategies, including producer cell engineering, viral-glycoprotein pseudotyping, and post-isolation surface modifications, this tropism can be expanded or redirected toward cell types and tissues beyond the liver. Here, we review the biology underlying cell-derived particle surface composition and the targeting strategies employed to engineer cell-type specificity.
    DOI:  https://doi.org/10.1016/j.cbpa.2026.102815
  15. Pharmacol Res. 2026 Nov 05. pii: S1043-6618(26)01654-3. [Epub ahead of print] 109739
      Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which treatment options remain limited. Extracellular vesicles (EVs) offer a potential cell-free therapeutic approach, but limited brain exposure after systemic administration remains a major obstacle. Mesenchymal stem-like cells derived from human brain organoids (hBO-MSCs) may provide an alternative EV source with a molecular profile shaped by the neural culture environment. This study aimed to generate RDP-modified hBO-MSC-EVs and evaluate their physicochemical characteristics, acute safety, brain-associated biodistribution, and treatment-associated effects in the 5×FAD mouse model of AD. hBO-MSCs were isolated from dorsal forebrain-like human brain organoids and engineered to express an RDP-Lamp2b-HA fusion protein. EV preparations were characterized by morphology, particle measurements, EV-associated protein markers, and relative RDP-Lamp2b-HA abundance. Brain-associated biodistribution and acute safety were assessed in C57BL/6J mice, whereas treatment-associated outcomes were evaluated in 5×FAD mice receiving PBS, unmodified hBO-MSC-EVs, or hBO-MSC-RDP-EVs. Behavioral testing, hippocampal Aβ histopathology, and exploratory transcriptomic profiling were used to assess the response. Following intravenous administration, RDP modification was associated with greater brain-associated fluorescence than unmodified EVs, without evidence of overt acute organ histopathology or a consistent systemic pro-inflammatory response at the tested endpoints. In 5×FAD mice, hBO-MSC-RDP-EV treatment was associated with improvements in selected behavioral measures, most consistently in the Morris water maze, together with reduced histologically detectable hippocampal Aβ plaque burden and changes in inflammation- and neuronal-associated transcripts. These findings warrant further preclinical evaluation of surface-engineered hBO-MSC-EVs as a candidate cell-free approach for AD. Intact-EV blood-brain barrier transport, cargo-dependent mechanisms, source-specific advantages, and long-term safety remain unestablished.
    Keywords:  Alzheimer's disease; Brain organoid; Brain targeting; Extracellular vesicles; Mesenchymal stem cells
    DOI:  https://doi.org/10.1016/j.phrs.2026.109739